Progesterone is named as an intervention in 9 current clinical trials in our China, France, Spain, Netherlands, Belgium, Denmark, Japan, Israel and Egypt registers. 7 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is West China Second University Hospital (1). The most-studied condition is Infertility. The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Progesterone. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Effects of Menopausal Hormone Therapy on QTc in Genetically Confirmed Long QT Syndrome: A Prospective Randomized Sequential Crossover Study with Long-Term Observational Follow-Up (LQTS-HER)
2026-526442-28-00 · Cardiovascular Diseases
|
Phase 4 | Authorised | Oslo Universitetssykehus HF | Norway |
|
Progesterone Luteal Support in Unexplained Infertility Management (PLUIM study)
2026-525747-33-00 · CTIS ↗ · Reproductive and Urinary Physiological Phenomena
|
Phase 4 | Authorised | Universitair Medisch Centrum Utrecht | Netherlands |
|
The impact of ovarian stimulation with hMG on embryo quality in advanced age women. A randomized controlled trial
2025-524761-25-00 · CTIS ↗ · Female Urogenital Diseases and Pregnancy Complications
|
Phase 4 | Authorised | Santiago Dexeus Font Fundacio Privada | Spain |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
11 single-substance products containing Progesterone on the HPRA medicines list.
No entry for Progesterone in the EMA, FDA or German BfArM shortage lists we track.
| Condition (as registered) | Trials |
|---|---|
| Infertility | 2 |
| Endometrial Cancer | 1 |
| Atypical Endometrial Hyperplasia | 1 |
| Pregnancy | 1 |
| Progesterone Supplementation | 1 |
| Low Serum Progesterone | 1 |
| Infertilities | 1 |
| Embryo Transfer | 1 |
| Endometrial Cancer Stage III | 1 |
| Endometrial Cancer Stage IV | 1 |
| Endometrial Cancer Recurrent | 1 |
| Fertility | 1 |
| Implantation, Embryo | 1 |
| GnRH Antagonist IVF Protocol | 1 |
| Fresh Embryo Transfer | 1 |
| Administration of Hormonal Luteal Support | 1 |
| Low Dose | 1 |
| Progesterone | 1 |
| Triggering Ovulation | 1 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
9 current trials in our China, France, Spain, Netherlands, Belgium, Denmark, Japan, Israel and Egypt registers name Progesterone as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 7 of the 9 trials are recruiting: 1 with sites in China, 1 with sites in Spain, 1 with sites in Netherlands, 1 with sites in Denmark, 1 with sites in Japan, 1 with sites in Israel and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
West China Second University Hospital (1), University Hospital, Montpellier (1), Fundacion Clinic per a la Recerca Biomédica (1) and Radboud University Medical Center (1), among 9 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 11 single-substance products containing Progesterone, for example Crinone 8% w/w progesterone vaginal gel (Merck Serono (Ireland) Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Progesterone has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Progesterone works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Progesterone works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Progesterone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.